![Clarissa Sowemimo-Coker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Clarissa Sowemimo-Coker
Vorstandsvorsitzender bei OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC
Vermögen: 4 300 $ am 31.05.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Indraneil Mahapatra | M | 44 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 7 Jahre |
Charanjit Dhillon | F | 66 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
Julie Pomeroy | F | 69 | - | |
Timothy Corn | M | 73 | 1 Jahre | |
Karen Lowe | F | 55 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
John Lucas | M | 58 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 3 Jahre |
Paul Smalley | M | - | 2 Jahre | |
Robin Bennett | M | - | 2 Jahre | |
Richard Hathaway | M | 57 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
Bishrut Mukherjee | M | 37 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
Valentino Parravicini | M | 55 | 4 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Hee-Dong Kim | M | - |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 12 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Clarissa Sowemimo-Coker
- Persönliches Netzwerk